<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818141</url>
  </required_header>
  <id_info>
    <org_study_id>NICO003785HE</org_study_id>
    <nct_id>NCT01818141</nct_id>
  </id_info>
  <brief_title>Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin</brief_title>
  <official_title>An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optimer Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare number of vegetative cells and spores in stool over
      time for fidaxomicin or vancomycin in patients diagnosed with their first episode of C.
      difficile infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to:

        -  Compare quantitatively the number of vegetative cells in stool over time for fidaxomicin
           or vancomycin in patients diagnosed with their first episode of C. difficile infection

        -  Compare quantitatively the number of spores in the stool over time for patients
           presenting with their first episode of C. difficile infection having been treated with
           either fidaxomicin or vancomycin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2012</start_date>
  <completion_date type="Actual">December 15, 2014</completion_date>
  <primary_completion_date type="Actual">December 15, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</measure>
    <time_frame>day 10-13</time_frame>
    <description>The number and percentage of patients who achieved at least 2 log10 colony forming units (CFU)/g of stool reductions of Clostridium difficile spores from baseline by the end of therapy (days 10-13).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</measure>
    <time_frame>day 10-13</time_frame>
    <description>The number and percentage of patients who achieved at least 2 log10 CFU/g of stool reductions of Clostridium difficile vegetative cells from baseline by the end of therapy (days 10-13)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Fidaxomicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 125mg by mouth every 6 hours for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 125mg by mouth every 6 hours for 10 days</description>
    <arm_group_label>Vancomycin</arm_group_label>
    <other_name>Vancomycin 125mg by mouth every 6 hours for 10 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fidaxomicin</intervention_name>
    <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
    <arm_group_label>Fidaxomicin</arm_group_label>
    <other_name>Fidaxomicin 200mg by mouth every 12 hours for 10 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and above

          -  First diagnosis of C. difficile infection

          -  Treatment for C. difficile infection less than 24 hours

          -  Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at
             least 1 year, surgically sterile (i.e., documented tubal ligation or hysterectomy) for
             at least 90 days, abstinent, or agree to use 1 of the following forms of contraception
             from the time of signing the Informed Consent form (ICF) until 30 days after leaving
             the study site: a nonhormonal intrauterine device (IUD) with spermicide, female condom
             with spermicide, contraceptive sponge with spermicide, diaphragm with spermicide,
             cervical cap with spermicide, a male sexual partner who agrees to use a male condom
             with spermicide, or a sterile sexual partner.

        Exclusion Criteria:

          -  History of hypersensitivity to fidaxomicin or vancomycin

          -  Pregnant or breast-feeding

          -  Active treatment with other therapies with activity against C. difficile

          -  Receiving any peristaltic agents

          -  Medical history including ulcerative colitis or Chron's disease

          -  Ordered to be nothing by mouth or cannot swallow the study medication

          -  Participation in another clinical research study utilizing pharmacological treatment
             within 1 month or five half-lives of the medication whichever is longer

          -  Any other reason felt by the investigator to potentially affect the outcomes of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infect Control Hosp Epidemiol. 2016 Feb;37(2):215-8. doi: 10.1017/ice.2015.270. Epub 2015 Nov 23.</citation>
    <PMID>26592763</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>May 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fidaxomicin</title>
          <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days
Fidaxomicin: Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>Vancomycin 125mg by mouth every 6 hours for 10 days
Vancomycin: Vancomycin 125mg by mouth every 6 hours for 10 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No baseline C.diff colonies</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fidaxomicin</title>
          <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days
Fidaxomicin: Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>Vancomycin 125mg by mouth every 6 hours for 10 days
Vancomycin: Vancomycin 125mg by mouth every 6 hours for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="15"/>
                    <measurement group_id="B2" value="66" spread="15"/>
                    <measurement group_id="B3" value="67" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline total colony forming units (CFU)</title>
          <description>Total colony forming units (CFU) of Clostridium difficile per patient at baseline. This is the addition of vegetative cell counts and spore cell counts.</description>
          <units>log10 CFU/g stool</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.41" spread="1.72"/>
                    <measurement group_id="B2" value="4.96" spread="1.81"/>
                    <measurement group_id="B3" value="5.19" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline spores CFU</title>
          <description>The count (colony forming units, CFU) of Clostridium difficile spores at baseline stool.</description>
          <units>log10 CFU/g stool</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.00" spread="1.44"/>
                    <measurement group_id="B2" value="4.87" spread="1.43"/>
                    <measurement group_id="B3" value="4.94" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline vegetative cells CFU</title>
          <description>Count (colony forming units, CFU) of vegetative Clostridium difficile in baseline stool.</description>
          <units>log10 CFU/g stool</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.23" spread="2.39"/>
                    <measurement group_id="B2" value="4.22" spread="2.1"/>
                    <measurement group_id="B3" value="4.23" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</title>
        <description>The number and percentage of patients who achieved at least 2 log10 colony forming units (CFU)/g of stool reductions of Clostridium difficile spores from baseline by the end of therapy (days 10-13).</description>
        <time_frame>day 10-13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fidaxomicin</title>
            <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days
Fidaxomicin: Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin 125mg by mouth every 6 hours for 10 days
Vancomycin: Vancomycin 125mg by mouth every 6 hours for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</title>
          <description>The number and percentage of patients who achieved at least 2 log10 colony forming units (CFU)/g of stool reductions of Clostridium difficile spores from baseline by the end of therapy (days 10-13).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</title>
        <description>The number and percentage of patients who achieved at least 2 log10 CFU/g of stool reductions of Clostridium difficile vegetative cells from baseline by the end of therapy (days 10-13)</description>
        <time_frame>day 10-13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fidaxomicin</title>
            <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days
Fidaxomicin: Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Vancomycin 125mg by mouth every 6 hours for 10 days
Vancomycin: Vancomycin 125mg by mouth every 6 hours for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool</title>
          <description>The number and percentage of patients who achieved at least 2 log10 CFU/g of stool reductions of Clostridium difficile vegetative cells from baseline by the end of therapy (days 10-13)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fidaxomicin</title>
          <description>Fidaxomicin 200mg by mouth every 12 hours for 10 days
Fidaxomicin: Fidaxomicin 200mg by mouth every 12 hours for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>Vancomycin 125mg by mouth every 6 hours for 10 days
Vancomycin: Vancomycin 125mg by mouth every 6 hours for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David P. Nicolau, PharmD, FCCP, FIDSA</name_or_title>
      <organization>Hartford Hospital</organization>
      <phone>860-972-3941</phone>
      <email>david.nicolau@hhchealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

